Clinical Study to Evaluate the Tolerability, Safety and Efficacy of Enteric-coated Mycophenolate Sodium After Equimolar Conversion From Mycophenolate Mofetil (MMF) in Patients With Renal Transplant

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00171379
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : February 2, 2011
Information provided by:

Brief Summary:
The aim of the study is to evaluate the safety and efficacy of equimolar conversion from MMF to enteric-coated mycophenolate sodium, in renal transplant patients receiving cyclosporine.

Condition or disease Intervention/treatment Phase
Prevention of Acute Rejection After Kidney Transplantation Drug: Enteric-Coated Mycophenolate Sodium Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 162 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Open-label Study to Evaluate the Tolerability, Safety and Efficacy of the Equimolar Conversion From Mycophenolate Mofetil (MMF) to Enteric-Coated Mycophenolate Sodium (EC-MPS) in Patients With Renal Transplant
Study Start Date : March 2004
Actual Primary Completion Date : June 2005
Actual Study Completion Date : June 2005

Primary Outcome Measures :
  1. Renal function, measured as calculated creatinine clearance according to the Cockcroft and Gault formula

Secondary Outcome Measures :
  1. Incidence of biopsy proven acute rejection
  2. Overall Gastrointestinal disturbances as measured by visual analog scales (upper and lower gastrointestinal symptoms)
  3. Quality of life related to GI symptoms (GIQLI scale)
  4. Full blood count
  5. Gastrointestinal Adverse Events (check-list)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • First or second (single or double) deceased or living donor kidney transplant received at least six months previously;

    • Immunosuppressive therapy with cyclosporin and mycophenolate mofetil (MMF);
    • Receiving an MMF dose of <2/g/day because of any adverse event and/or altered laboratory test result attributed to MMF

Exclusion Criteria:

  • • Subjects expected to discontinue cyclosporin therapy;

    • Patients with thrombocytopenia (<75,000/mm3), an absolute neutrophil count of <1,500/mm3 and/or leukopenia (<2,500/mm3), or anemia (hemoglobin <6 g/dl) at baseline;
    • Patients experiencing an acute rejection in the previous two months, with inadequate (creatininemia >2.5 mg/dL) or worsening renal function in the previous two months.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00171379

Sponsors and Collaborators
Study Director: Novartis Novartis

Responsible Party: Novartis External Affairs, Novartis Pharmaceuticals Identifier: NCT00171379     History of Changes
Other Study ID Numbers: CERL080AIT01
First Posted: September 15, 2005    Key Record Dates
Last Update Posted: February 2, 2011
Last Verified: February 2011

Keywords provided by Novartis:
Kidney transplantation; acute rejection; gastrointestinal adverse events; quality of life; mycophenolate sodium.

Additional relevant MeSH terms:
Mycophenolic Acid
Antibiotics, Antineoplastic
Antineoplastic Agents
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action